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Purpose: To examine the psychometric properties of the Injection Pen Assessment Questionnaire (IPAQ) including
the following: 1) item and scale characteristics (e.g., frequencies, item distributions, and factor structure),
2) reliability, and 3) validity.
Methods: Focus groups and one-on-one dyad interviews guided the development of the IPAQ. The IPAQ was
subsequently tested in 136 parent–child dyads in a Phase 3, 2-month, open-label, multicenter trial for a new
GenotropinW disposable pen. Factor analysis was performed to inform the development of a scoring algorithm, and
reliability and validity of the IPAQ were evaluated using the data from this two months study. Psychometric
analyses were conducted separately for each injection pen.
Results: Confirmatory factor analysis provides evidence supporting a second order factor solution for four subscales
and a total IPAQ score. These factor analysis results support the conceptual framework developed from previous
qualitative research in patient dyads using the reusable pen. However, the IPAQ subscales did not consistently meet
acceptable internal consistency reliability for some group level comparisons. Cronbach’s alphas for the total IPAQ
score for both pens were 0.85, exceeding acceptable levels of reliability for group comparisons.
Conclusions: The total IPAQ score is a useful measure for evaluating ease of use and preference for injection pens
in clinical trials among patient dyads receiving hGH. The psychometric properties of the individual subscales, mainly
the lower internal consistency reliability of some of the subscales and the predictive validity findings, do not
support the use of subscale scores alone as a primary endpoint.
Keywords: Patient-reported outcome, Injection device (pen), Ease of use, Parent–child dyads, Growth hormone (GH)Introduction
Human growth hormone (hGH) is produced and
excreted by the anterior pituitary gland to help fuel
growth during childhood and to maintain tissues and
organs throughout life [1]. In recent decades, recombin-
ant hGH has been used to treat short stature or growth
failure in children, including the following: 1) growth
hormone deficiency, 2) born small for gestational age, 3)
Prader-Willi syndrome, 4) Turner syndrome, 5) chronic
renal insufficiency, and 6) idiopathic short stature. Most* Correspondence: andreas.m.pleil@pfizer.com
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reproduction in any medium, provided the orchildren receive injections daily and treatment usually is
carried out over several years, until the child achieves an
acceptable adult height or maximum growth [2].
In order to achieve optimal therapeutic results, adher-
ence to long-term, continuous hGH administration is
essential [3]. Ease of use is recognized by parents, physi-
cians and nurses as a key feature in device acceptance
[3] with potential to improve adherence. Injection
devices, such as pre-filled syringes and manual injector
pens, have been developed to make the process of pre-
paring and administering hGH easier and more conveni-
ent. There are several different injection devices
available on the market, including the GenotropinW pen. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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order to prepare the pen and to inject the hGH, includ-
ing inserting a cartridge, mixing the medicine, inserting
a needle, getting rid of air bubbles, using the needle
guard, choosing or dialing the dose and finally injecting
hGH. Depending on the age of the child, either the par-
ent, the child, or both participate in preparing the injec-
tion pen and administering the medication. As such,
patient-reported outcomes (PRO) measures developed to
assess these injection devices should include feedback
from both parents and children to better reflect how
these devices are used in practice.
Another reason for obtaining parent–child opinions
together is based on findings from the literature suggest-
ing variability in perceptions of disease impact between
parent and child in health-related quality of life (HRQL)
[4-8]. It has been suggested that good parent–child
agreement is seen for items that are concrete and ob-
servable (e.g., physical aspects of health), and poor
agreement for items that require judgment (e.g., emo-
tional or social aspects of health). However, a recent re-
view of the literature suggests that levels of parent–child
agreement may be influenced by the relevance of a do-
main to a disease and to the consequent parental in-
volvement to care for the child [8], not merely by the
objectivity of the domain. That is, parent–child agree-
ment may be higher when the parent is more involved in
caring for the child in a domain that is more influenced
by disease. For example, in patients with rheumatoid arth-
ritis, in which physical function is impacted, parents may
need to provide more assistance with physical activities
and may be more aware of their child’s physical function-
ing, resulting in stronger agreement on domains that
measure the physical impact of disease. In this population,
concordance in HRQL scores between parents and
children was 0.71 for physical functioning, which was
stronger than concordance for emotional functioning and
worry (r = 0.51 and 0.48, respectively) [9].
For measures that evaluate domains or activities with
high parent–child involvement, such as injection pen
preparation and use, a dyadic approach may be useful to
overcome concordance issues that arise in obtaining in-
formation separately from the parent-child. Although
little research has been conducted to evaluate the
parent-child dyad relationship in developing PRO ques-
tionnaires or in responding to PRO questionnaires, a
qualitative analysis of parent–child dyad approach by
Ungar and colleagues [10] suggests that a dyadic ap-
proach could be helpful to children in enabling them to
answer questionnaire items as accurately as possible.
When responding to HRQL questionnaires together,
parents were a valuable resource to their children (ages
8–15 years) and helped them overcome problems with
recall or comprehension that they may have had withthe questionnaire. It was noted that child participants
would look to their parents to corroborate answers, help
remember events and clarify the meaning of questions,
words or phrases. Additional studies are needed to bet-
ter understand this methodological approach, including
evaluations of the psychometric properties of measures
that are administered to parent and children together.
The Injection Pen Assessment Questionnaire (IPAQ)
was developed to evaluate patient (i.e., children 8 to
18 years old) and parent perceptions of ease of use and
preference for attributes of injection pens used to ad-
minister hGH. The questionnaire was designed to be
administered to parent–child dyads, where dyads to-
gether are asked to complete a single copy of the ques-
tionnaires. The objectives of this study were to examine
the psychometric properties of the IPAQ including the
following: 1) item and scale characteristics (e.g., frequen-
cies, item distributions, and factor structure), 2) reliabil-
ity, and 3) validity.
Study methods
Instrument development
The IPAQ was developed through a scientifically rigor-
ous, systematic process [11]. First, four focus groups
with parent–child dyads were conducted to identify key
issues and concerns about use of injection pens to ad-
minister hGH, as well as to learn the language that
dyads use to describe the attributes of injection pens.
Based on information collected, a working draft ques-
tionnaire was developed. Following this, one-on-one
cognitive debriefing interviews were conducted with
eight parent–child dyads with previous experience using
a pre-specified injection pen to ensure that items in the
working draft questionnaire were easy to complete, well
understood and relevant to their experience. Findings
obtained from each step in the item generation and se-
lection process were reviewed by the research team, in-
cluding two psychometricians and two clinicians (one
endocrinologist), >and provided recommendations to
ensure face validity. In addition, a translation expert
reviewed the draft questionnaire and provided feedback
about words or phrases that may be structurally or cul-
turally problematic when translated into different lan-
guages. A total of 29-items were included in the draft
IPAQ: 1) fourteen items evaluating ease of use for a sin-
gle injection pen, 2) fourteen items comparing ease of
use between injection pens, and 3) one item evaluating
preference for an injection pen. The conceptual frame-
work was established (Figure 1) based on the results of
the focus group and cognitive debrief activities. Four
components of ‘ease of use” were hypothesized; 1) pre-
paring the pen; 2) setting the dose; 3) injecting the medi-
cine and; 4) maintaining. The questionnaire was then
























Disposing of the cartridge/device 
Handling the device
Figure 1 Conceptual Framework Model for the Injection Pen Assessment Questionnaire.
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to evaluate its psychometric characteristics (i.e., reliability,
validity). The results of the study’s primary endpoint are
reported elsewhere [12].Psychometric evaluation study
One-hundred-thirty six parent–child dyads were
recruited from 20 study sites across the United States
into a Phase 3 trial to evaluate a new GenotropinW dis-
posable injection pen (“new disposable pen”). The trial
was an open-label, non-comparative, single-arm, multi-
center study with a duration of treatment of 2 months.
All subjects, based on the child member of the dyad,
met the following inclusion criteria: 1) age ≥8 years and
≤18 years, 2) currently on treatment with GenotropinW
Pen ≥3 months, 3) compliant with current GenotropinW
Pen treatment, 4) able to understand English, and 5)
have a negative urine pregnancy test at screening, if of
childbearing potential. If possible, assent was obtained
from the child. Adult members of the dyad needed to: 1)
provide written informed consent and 2) be able to read
English and understand English. In addition, dyads
needed to be willing and able to comply with scheduled
visits, treatment plan, and other study procedures. Dyads
using other hGH injection devices other than the
current reusable GenotropinW Pen were excluded.Written informed consent was obtained for subjects
prior to screening. Upon screening and prior to intro-
duction to the new disposable pen (Visit 1), parent–child
dyads completed Section I of the IPAQ to assess their
opinion/view regarding the ease of using their current
reusable pen. Next, subjects and caregivers were
instructed in the proper use of the new disposable pen
and were asked to use the new pen for two months. A
telephone follow-up contact (Visit 2) occurred at day 7
to assess safety and address any subject questions. After
two months of using the new disposable pen, dyads were
asked to return to the clinic to complete Sections I and
II of the IPAQ (Visit 3) regarding their experience with
the new disposable pen (i.e., ease of use and preference
for a specific injection pen, respectively). Instructions on
questionnaire completion were provided to all dyads by
trained personnel.Clinical and patient-reported outcome measures
The IPAQ is a 29-item instrument that can be used to
measure preference for an injection device from the per-
spective of the subject. The IPAQ is divided into two
sections. Section I is designed to measure ease of use
attributes (13 items) and “overall ease of use” (1 item) of
a single pen. Items in Section I are rated on 5 point scale
from “very easy” to “very difficult”. Section II compares
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of use attributes (13 items) and overall ease of use
(1 item) as Section I. Response options include “Geno-
tropinW Pen easier to use”, “New injection pen easier to
use” or “no difference”. An additional item is included in
Section II, which asks dyads to rate their overall prefer-
ence for a device as “Prefer GenotropinW Pen”, “Prefer
new injection pen” or “no preference”.
Demographic and clinical variables such as date of
birth, gender, race, ethnicity, height, weight and primary
diagnosis were collected at screening/baseline.Psychometric analysis
Analyses were performed to examine the following psy-
chometric characteristics of the IPAQ in measuring ease
of use/convenience and preference for injection pens: 1)
item characteristics, 2) factor structure, 3) reliability, and
4) validity. Responsiveness analyses were not conducted
because subjects did not evaluate the same injection pen
using the IPAQ at two time points during this trial, which
is required for this type of analysis. Analyses were con-
ducted: 1) using data from dyads that completed the IPAQ
for at least one time point and 2) separately for the indi-
vidual injection pens. All data analyses were performed
using SAS statistical software version 9.1 (Cary, NC).Item characteristics
Characteristics of individual items of the IPAQ were
examined by calculating the mean, minimum possible and
maximum possible response (i.e., floor and ceiling effects),
range, item frequency and item- to-item correlations. For
Section I of the IPAQ, assessments for injection pens were
conducted separately. Item analysis for Section II of the
IPAQ examining item scores by injection pen preference
was also conducted.Factor structure and scoring
Confirmatory factor analysis (CFA) was used to examine
the hypothesized structure of the IPAQ based on the
conceptual framework developed through dyad inter-
views. Items within each of the four dimensions should
be uni-dimensional. A CFA was conducted to fit a 4-
factor model where each item was associated with one
pre-defined factor. Overall model fit statistics were
examined, as well as standardized regression coefficients
(factor loadings) for each item. Good model-fit is indi-
cated when Bentler Comparative Fit Index (CFI) is above
0.90 [13]. In addition, Root Mean Square Error of Ap-
proximation (RMSEA) should be below 0.05 as indica-
tion of good model-fit, or below 0.08 as acceptable
model fit.Subscale characteristics
To assess measurement properties of the resulting sub-
scales from the factor analysis, subscale scores were cal-
culated according to the proposed scoring guidelines,
with higher scores indicating better outcomes. Distribu-
tional characteristics of the subscales were assessed, in-
cluding means, floor and ceiling effects, and ranges. The
subscale to subscale correlations also were assessed.
Reliability
Cronbach’s alpha was used to assess internal consistency
of subscales generated by the CFA and total score for
the IPAQ. Coefficient values that are greater than 0.70
are generally considered acceptable for aggregate data
[14,15].
Validity
Spearman rank correlation coefficients were used to
evaluate construct validity of the IPAQ through correla-
tions between the IPAQ subscales and the “overall ease
of use” item (Item 1 of Section I). Construct validity was
supported when a specific subscale is substantially corre-
lated (>0.40) with “overall ease of use” item. For inter-
pretation, guidelines suggested by Cohen [16]were used,
where absolute correlation values between 0.10 and 0.29
are considered weak, 0.30 to 0.49 are considered moder-
ate, and 0.50 to 1.00 are considered strong.
Logistic regression analyses were performed to assess
the relationship between IPAQ subscales and preference
for a specific injection pen and to determine whether
the predicting subscales (i.e., pen characteristics) are the
same regardless of which injection pen dyads preferred.
The first analysis evaluated the relationship between pre-
ference for an injection pen at Visit 3 and subscale
scores for the reusable injection pen at Visit 1. Injection
pen preference was categorized as “prefer reusable pen”
and “prefer new disposable pen or no preference”. The
regression model was: injection pen preference = score
for preparing the pen + score for setting the dose + score
for injecting the medicine + score for maintaining the
pen + age + gender. The second analysis evaluated the re-
lationship between preference for an injection pen at
Visit 3 and subscale scores for the new disposable pen at
Visit 3. Injection pen preference was categorized as “pre-
fer new disposable pen” and “prefer reusable pen or no
preference”. The regression model was: injection pen
preference = score for preparing the pen + score for set-
ting the dose + score for injecting the medicine + score
for maintaining the pen + age + gender.
Tests of general association using the Mantel-Haenzel
estimate of the common odds ratio also were used to as-
sess the relationship between IPAQ comparative ease of
use items and preference for a specific injection pen to
determine if a rating for individual attributes is associated
Table 1 Demographic and clinical characteristics of hGH
recipient at screening/baseline
Total (N = 136)
Age (years), mean (SD) 12.3 (2.4)
Gender, n (%male) 91 (66.9%)
Height (inches), mean (SD) 57.5 (5.6)








Not Hispanic/Latino 124 (91.2%)
Primary diagnosis, n (%)
Dwarfism 1 (0.7%)
Fetal growth retardation 1 (0.7%)
Hypopituitarism 3 (2.2%)
Hypopituitarism fetal 1 (0.7%)
Small for gestational age 28 (20.6%)
Turner's syndrome 10 (7.4%)
Growth retardation 15 (11.0%)
Growth hormone deficiency 72 (52.9%)
Body height below normal 4 (2.9%)
Silver-Russell syndrome 1 (0.7%)
Time since diagnosis (years), mean (SD) 5.6 (4.3)
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ence was categorized as “prefer reusable pen or no prefer-
ence” or “prefer new disposable pen” and ease of use items
were categorized as “reusable pen easier to use or no differ-
ence” or “new disposable pen easier to use”. The Mantel-
Haenzel tests were run for each individual injection pen at-
tribute. The attributes are: attaching/removing needle, pre-
paring the injection pen, mixing the medicine, removing
the air bubbles, remembering the dose, setting the dose,
changing the dose for prescription changes, using the nee-
dle guard, injecting the medicine, knowing when the injec-
tion was finished, handling the pen, storing the pen,
disposing of the cartridge/pen and “overall ease of use”.
Gender was included in the Mantel-Haenzel tests as a
stratification factor.
Additional analyses
To determine which items most influence preference,
between-group differences in item ratings were assessed
using chi-square analyses, where groups were defined
based on preferences for a device (i.e., prefer reusable pens,
prefer new disposable pen). Visit 1 ratings were used for
dyads who preferred reusable pen and were compared with
Visit 3 ratings for those who preferred new disposable pen.
Item responses were grouped into two categories: “very
easy” and “not very easy”, which includes all other response
options (“somewhat easy”, “neither easy nor difficult”,
“somewhat difficult” and “very difficult”). In addition, dif-
ferences in item ratings were assessed between Visits 1 and
3 within each preference groups (i.e., prefer reusable pen
or prefer new disposable pen) using ICC analyses, to deter-
mine which items most impacted preference.
Results
Dyad characteristics
A total of 136 dyads were included in the psychometric
analysis. This included one dyad that completed the assess-
ments for Visit 3 outside of the specified time window.
Characteristics of the child (subject) member of the dyad
are summarized in Table 1. Subjects were primarily boys
(66.9%), white (84.6%), non-Hispanic/Latino (91.2%) and
were an average of 12.3 years old. Growth hormone defi-
ciency (52.9%) was the most frequently reported primary
diagnosis, followed by small for gestational age (20.6%),
and growth retardation (11.0%). Subjects had been diag-
nosed for an average of 5.6 years (sd 4.3) prior to the study.
Almost all of the adult dyad members (82.4%) were
subjects’ mothers. The majority of the adult dyad
members were responsible for preparing the injection
and administering the injection (82.4% and 73.5%,
respectively) (Table 2). On average, dyads reported hav-
ing used the reusable pen for 4.0 years (Table 2). The
majority of subjects use the 12 mg GenotropinW reusable
pen (94.1%).Item characteristics
IPAQ item scores range from 1 (very difficult) to 5 (very
easy). Items 2 g (“changing the dose when the doctor
changes the prescription” and 2 h (“using the needle
guard”) followed a skip pattern, where subjects who did
not have a dose change or did not use the needle guard
skipped these items. For the reusable and new disposable
injection pens, 21.3% and 80.6%, respectively, did not re-
port a change in dosage during the observation period.
In addition, approximately 20% of subjects did not use a
needle guard with either pen.
For the reusable pen, mean Section I IPAQ scores ran-
ged from 3.4 to 4.8 (Table 3). For eight of the thirteen
IPAQ items, greater than 50% of dyads scored at the
ceiling (“very easy”). Mean Section I IPAQ scores for the
new disposable pen ranged from 4.1 to 4.8 (Table 4). In
the case of the new disposable pen, all 13 items had 50%
of more respondents reporting at the ceiling (very easy).
Factor analysis and scoring algorithm
CFA was conducted to substantiate a second order
model, based on the conceptual framework for the
Table 2 Injection pen and IPAQ respondent
characteristics
Total (N = 136)





Length of time using reusable pen(years), mean (SD) 4.0 (3.1)
Type of Pen, n (%)
5 MG 8 (5.9%)
12 MG 128 (94.1%)













Table 3 IPAQ item distributional characteristics for Section I (
1. Ease or difficulty of using the injection pen overall
2a. Attaching and removing the needle
2b. Preparing the injection pen by changing the cartridge or getting a new i
2c. Mixing the medicine
2d. Removing the air bubbles
2e. Remembering the dose that was prescribed by the doctor
2f. Setting the dose
2g. Changing the dose when the doctor changes the prescription3
2h. Using the needle guard3
2i. Injecting the medicine
2j. Knowing when the injection pen has finished injecting the medicine
2k. Handling the injection pen while preparing and injecting the medicine
2l. Storing the injection pen in the refrigerator
2m. Disposing of the cartridge or disposing of the injection pen
1Assessment of reusable pen (Visit 1).
2Floor indicates “Very Difficult” and ceiling indicates “Very Easy”.
3Percentage based on the number of dyads who changed the dose (N = 107) or use
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development of the IPAQ, shows individual items (injec-
tion pen attributes) fitting into 4 subscales (preparing
the pen, setting the dose, injecting the medicine and
maintaining the pen) and the 4 subscales fit under a
total ease of use domain. Findings from the CFA suggest
that Item 2 k (“Handing the injection pen while prepar-
ing and injecting the medicine”) belongs in the subscale
for injecting the medicine, rather than the subscale for
maintaining the injection pen, as in the conceptual
model based on dyad interviews. As such, Item 2 k was
included in the “injecting the medicine” subscale.
CFA of the IPAQ showed evidence of a second order fac-
tor model (Tables 5 and 6). For the first order factor model
[preparing the pen (4 items), setting the dose (3 items),
injecting the medicine (4 items) and maintaining the pen
(2 items)], loadings for all items within each factor
exceeded 0.40 with the majority being higher than 0.60.
Loading ranged from 0.57 to 0.85 for the reusable pen
(Table 5) and from 0.59 to 0.96 for the new disposable pen
(Table 6). The subscales loaded on the total ease of use do-
main, with loadings ranging from 0.79 to 0.94 for the re-
usable pen (Table 5) and from 0.63 to 0.97 for the new
disposable pen (Table 6). Fit indices for the reusable pen
were: CFI = 0.952 and RMSEA = 0.080. Fit indices for the
new disposable pen were: CFI = 0.984 and RMSEA = 0.051.
The final scoring algorithm for the 13 Section I IPAQ
items, excluding Item 1, therefore, consisted of four sub-
scale scores (preparing the pen, setting the dose, injecting
the medicine and maintaining the pen). Each subscale
score is calculated by summing the value of individual
items within a subscale. A total score (total IPAQ score),reusable pen)1,2
N Mean SD Floor (%) Ceiling (%) Range
136 4.2 0.9 1 (0.7%) 58 (42.6%) 1.0-5.0
136 4.6 0.8 0 (0.0%) 98 (72.1%) 2.0-5.0
njection pen 136 3.8 1.1 2 (1.5%) 38 (27.9%) 1.0-5.0
136 4.2 1.0 0 (0.0%) 67 (49.3%) 2.0-5.0
136 3.7 1.1 4 (2.9%) 42 (30.9%) 1.0-5.0
136 4.8 0.6 0 (0.0%) 112 (82.4%) 3.0-5.0
136 4.7 0.8 1 (0.7%) 108 (79.4%) 1.0-5.0
107 4.8 0.6 0 (0.0%) 90 (84.1%) 2.0-5.0
111 4.6 0.6 0 (0.0%) 78 (70.3%) 2.0-5.0
136 4.3 1.0 3 (2.2%) 71 (52.2%) 1.0-5.0
136 3.4 1.4 12 (8.8%) 42 (30.9%) 1.0-5.0
136 4.2 0.9 1 (0.7%) 62 (45.6%) 1.0-5.0
136 4.7 0.8 0 (0.0%) 110 (80.9%) 2.0-5.0
136 4.6 0.7 0 (0.0%) 99 (72.8%) 2.0-5.0
d the needle guard (N = 111).
Table 4 IPAQ item distributional characteristics for Section I (new disposable pen)1,2
N Mean SD Floor (%) Ceiling (%) Range
1. Ease or difficulty of using the injection pen overall 134 4.3 1.0 1 (0.7%) 75 (56.0%) 1.0-5.0
2a. Attaching and removing the needle 134 4.8 0.6 0 (0.0%) 116 (86.6%) 2.0-5.0
2b. Preparing the injection pen by changing the cartridge or getting a new injection pen 134 4.5 0.8 1 (0.7%) 91 (67.9%) 1.0-5.0
2c. Mixing the medicine 134 4.6 0.6 0 (0.0%) 95 (70.9%) 2.0-5.0
2d. Removing the air bubbles 134 4.6 0.7 0 (0.0%) 94 (70.1%) 2.0-5.0
2e. Remembering the dose that was prescribed by the doctor 134 4.8 0.6 1 (0.7%) 117 (87.3%) 1.0-5.0
2f. Setting the dose 134 4.6 0.8 1 (0.7%) 100 (74.6%) 1.0-5.0
2g. Changing the dose when the doctor changes the prescription 26 4.7 0.8 0 (0.0%) 22 (84.6%) 2.0-5.0
2h. Using the needle guard3 107 4.5 0.8 0 (0.0%) 76 (71.0%) 2.0-5.0
2i. Injecting the medicine 134 4.1 1.2 3 (2.2%) 69 (51.5%) 1.0-5.0
2j. Knowing when the injection pen has finished injecting the medicine 134 4.1 1.2 4 (3.0%) 71 (53.0%) 1.0-5.0
2k. Handling the injection pen while preparing and injecting the medicine 134 4.3 1.1 1 (0.7%) 82 (61.2%) 1.0-5.0
2l. Storing the injection pen in the refrigerator 134 4.4 1.1 3 (2.2%) 98 (73.1%) 1.0-5.0
2m. Disposing of the cartridge or disposing of the injection pen 133 4.5 0.9 1 (0.8%) 99 (74.4%) 1.0-5.0
1Assessment of new disposable pen (Visit 3).
2Floor indicates “Very Difficult” and ceiling indicates “Very Easy”.
3Percentage based on the number of dyads who changed the dose (N = 26) or used the needle guard (N = 107).
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calculated. All subscale scores were transformed to a 0 to
100 scale, with higher scores reflecting greater ease of use.Table 5 Confirmatory factor analysis of IPAQ: factor loading f
FIRST ORDER (IPAQ Items)
2a. Attaching and removing the needle
2b. Preparing the injection pen by changing the cartridge or getting a new
injection pen
2c. Mixing the medicine
2d. Removing the air bubbles
2e. Remembering the dose that was prescribed by the doctor
2f. Setting the dose
2g. Changing the dose when the doctor changes the prescription
2h. Using the needle guard
2i. Injecting the medicine
2j. Knowing when the injection pen has finished injecting the medicine
2k. Handling the injection pen while preparing and injecting the medicine
2l. Storing the injection pen in the refrigerator
2m. Disposing of the cartridge or disposing of the injection pen





Item 1 is a single item subscale and is not included in the analysis.
CFI = 0.984.
Root Mean Square Error of Approximation (RMSEA) = 0.051.Subscale characteristics
Table 7 and b shows the distributional characteristics (i.e.
mean, floor and ceiling effects, and range) of the IPAQor ease of use for reusable pen (N = 136)











0.57 — — — —
0.68 — — — —
0.84 — — — —
0.79 — — — —
— 0.61 — — —
— 0.62 — — —
— 0.80 — — —
— — 0.74 — —
— — 0.71 — —
— — 0.73 — —
— — 0.76 — —
— — — 0.85 —
— — — 0.78 —
— — — — —
— — — — 0.79
— — — — 0.94
— — — — 0.91
— — — — 0.93
Table 6 Confirmatory factor analysis of IPAQ: factor loading for ease of use for new disposable pen (N = 134)











2a. Attaching and removing the needle 0.68 — — — —
2b. Preparing the injection pen by changing the cartridge or getting a new
injection pen
0.82 — — — —
2c. Mixing the medicine 0.77 — — — —
2d. Removing the air bubbles 0.72 — — — —
2e. Remembering the dose that was prescribed by the doctor — 0.79 — — —
2f. Setting the dose — 0.77 — — —
2g. Changing the dose when the doctor changes the prescription — 0.59 — — —
2h. Using the needle guard — — 0.88 — —
2i. Injecting the medicine — — 0.88 — —
2j. Knowing when the injection pen has finished injecting the medicine — — 0.70 — —
2k. Handling the injection pen while preparing and injecting the medicine — — 0.80 — —
2l. Storing the injection pen in the refrigerator — — — 0.69 —
2m. Disposing of the cartridge or disposing of the injection pen — — — 0.96 —
SECOND ORDER (IPAQ Scales) — — — — —
Preparing the pen — — — — 0.87
Setting the dose — — — — 0.97
Injecting the medicine — — — — 0.86
Maintaining the pen — — — — 0.63
Item 1 is a single item subscale and is not included in the analysis.
CFI = 0.984.
Root Mean Square Error of Approximation (RMSEA) = 0.051.
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pen, respectively. Subscales are scored from 0 to100 with
higher scores representing better outcomes (i.e., easier to
use). For the reusable pen (Table 7), mean subscale scores
ranged from 76.4 (preparing the pen) to 93.0 (setting the
dose). For two of the subscales, greater than 60% of the
dyads scored at the ceiling (setting the dose 62.5% and
maintaining the pen 66.9%). For the new disposable pen
(Table 8), mean subscale scores ranged from 80.6 (injecting
the medicine) to 92.5 (setting the dose). For two of the sub-
scales, greater than 60% of the dyads scored at the ceiling
(maintaining the pen 64.9% and setting the dose 69.4%).Table 7 IPAQ scale distributional characteristics - assessment
Subscale/Total Score N Mean SD
Overall ease of use 136 79.6 22.2
Preparing the pen 136 76.4 18.2
Setting the dose 136 93.0 12.4
Injecting the medicine 136 77.1 19.5
Maintaining the pen 136 91.1 16.0
Total IPAQ score 136 84.4 12.8
1Ceiling indicates “Very Easy” for all items in a subscale and floor indicates “Very DiSubscale to subscale correlations for the reusable pen,
moderate to strong, significant correlations were
observed between all the subscales (range 0.34 to 0.56,
all p < 0.0001), and significant correlations were
observed between the total IPAQ score and all subscales
(range 0.63 – 0.86, all p < 0.0001). For the new dispos-
able pen, moderate to strong, significant correlations
were observed between most of the subscales (range
0.23 to 0.53, all p < 0.01), and moderate to strong, sig-
nificant correlations were observed between the total
IPAQ score and all subscales (range 0.60 – 0.84, all p <
0.0001).eeusable pen (Visit 1)1
Floor (%) Ceiling (%) Range
1 (0.7%) 58 (42.6%) 0.0-100.0
0 (0.0%) 21 (15.4%) 31.3-100.0
0 (0.0%) 85 (62.5%) 33.3-100.0
1 (0.7%) 25 (18.4%) 0.0-100.0
0 (0.0%) 91 (66.9%) 37.5-100.0
0 (0.0%) 13 (9.6%) 42.7-100.0
fficult” for all items in a subscale.
Table 8 IPAQ scale distributional characteristics - assessment new disposable pen (Visit 3)1
Subscale/Total Score N Mean SD Floor (%) Ceiling (%) Range
Overall ease of use 134 82.6 23.8 1 (0.7%) 75 (56.0%) 0.0-100.0
Preparing pen 134 90.9 12.6 0 (0.0%) 64 (47.8%) 37.5-100.0
Setting the dose 134 92.5 14.5 0 (0.0%) 93 (69.4%) 25.0-100.0
Injecting the medicine 134 80.6 21.5 0 (0.0%) 47 (35.1%) 25.0-100.0
Maintaining the pen 134 86.2 21.9 0 (0.0%) 87 (64.9%) 12.5-100.0
Total IPAQ score 134 87.5 13.2 0 (0.0%) 30 (22.4%) 37.5-100.0
1Ceiling indicates “Very Easy” for all items in a subscale and floor indicates “Very Difficult” for all items in a subscale.
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Total IPAQ scores demonstrated high internal
consistency (Cronbach’s alpha = 0.85) for both Visit 1
(Geontropin Pen assessment) and Visit 3 (new dispos-
able pen assessment) (Table 9). Cronbach’s alpha for the
subscales ranged from 0.58 to 0.73 (reusable pen assess-
ment); with two scales (setting the dose and maintaining
the pen) having alphas less than 0.70. For the new dis-
posable pen assessment, Cronbach’s alpha for the
subscales ranged from 0.53 to 0.82; with three scales
having alphas less than 0.70 – likely due to the small
number of items within each scale (2 or 3 items) and the
large ceiling effects.Validity
Construct validity
For the reusable pen, moderate to strong, significant corre-
lations were found with three of the IPAQ subscales and
the “overall ease of use” item (preparing the pen, setting
the dose and injecting the medicine) (range 0.49 - 0.52, p <
0.0001). Strong, significant correlations also were seen be-
tween these three subscales and the “overall ease of use”
item for the new disposable pen (range 0.53 to 0.65, p <
0.0001). For both the reusable and new disposable pens,
total IPAQ scores correlated strongly with the “overall ease
of use” item (0.59 and 0.67, respectively; both p < 0.0001).Table 9 IPAQ internal consistency reliability
GenotropinW Pen1 New Disposable Pen2
# of Items Cronbach’s
Alpha
# of Items Cronbach’s
Alpha
Overall ease of use 1 — 1 —
Preparing the pen 4 0.70 4 0.68
Setting the dose 3 0.58 3 0.53
Injecting the
medicine
4 0.73 4 0.82
Maintaining the
pen
2 0.65 2 0.65
Total IPAQ score 13 0.85 13 0.85
1N = 136, Visit 1.
2N = 134, Visit 3.Predictive validity
Preference for the reusable Pen: IPAQ scales In the
pre-specified logistic regression model [i.e., preference
for the reusable pen vs. (preference for the disposable
pen + no preference) = age + gender + 4 IPAQ subscales],
results indicate that none of the individual subscales pre-
dict preference for the reusable pen. Being male, how-
ever, predicted preference – with males being less likely
to prefer the reusable pen (0.409 point estimate; confi-
dence interval 0.180 to 0.927). Similar findings were seen
for the post-hoc logistic regression model, which was
the same as the first with the inclusion of the “overall
ease of use” item. Findings from another post-hoc model
[i.e., preference for the reusable pen vs. (preference for
the disposable pen + no preference) = age + gender + total
IPAQ score] indicate that neither total IPAQ score, age
nor gender predict preference for the reusable pen.
Preference for the New disposable Pen: IPAQ scales
In the pre-specified logistic regression model [i.e., prefer-
ence for the new disposable pen vs. (preference for the
reusable pen + no preference) = age + gender + 4 IPAQ
subscales], results indicate that none of the individual
subscales predict preference for the new disposable pen.
When including the “overall ease of use” item (Item 1)
in the pre-specified model, “overall ease of use” pre-
dicted preference for the new disposable pen. Results in-
dicate that for each one-unit increase in “overall ease of
use” item score, we expect to see a 6.3% (1.063 point es-
timate; confidence interval 1.028 to 1.099) increase in
the odds of preferring the new disposable pen. When in-
cluding only the total IPAQ score in the model, the total
score predicted preference for the new disposable pen.
Results indicate that for each one-unit increase in total
IPAQ score, we expect to see a 10.6% (1.106 point esti-
mate; confidence interval 1.062 to 1.153) increase in the
odds of preferring the new disposable pen.
Mantel-haenzel estimate of common odds ratios:
IPAQ items Analysis was conducted to assess the rela-
tionship between ratings of injection pens as “easier to
use” and preference. Three ways of categorizing
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pen vs. (preference for the disposable pen + no prefer-
ence), 2) preference for the new disposable pen vs. (pre-
ference for the reusable pen + no preference) and 3)
preference for the reusable pen vs. preference for the
disposable pen. In general, similar findings were seen
among the models, where rating the new disposable pen
as “easier to use” overall being the strongest predictor of
preference for the new disposable pen (odds ratio for
Model 1: 46.4). The individual attributes that were rated
as “easier to use” for the new disposable pen and that
were the strongest predictors for preference for the new
disposable pen were: setting the dose, handling the pen,
removing the air bubbles and injecting the medicine
(odds ratios for Model 1: 25.0, 18.9, 17.8 and 17.7,
respectively).
Additional analyses
Comparing dyads who preferred the reusable pen to
those who preferred the new disposable pen, a higher
percentage of dyads rated 8 of the 13 attributes “very
easy” for the new disposable pen compared to “very
easy” for the reusable pen (attaching and removing the
needle, preparing the injection pen by changing the cart-
ridge or getting a new injection pen, mixing the medi-
cine, removing the air bubbles, remembering the dose
prescribed by the doctor, knowing when the injection
pen has finished injecting the medicine, handling the in-
jection pen while preparing and injecting the medicine;
all <0.05). Percentages of dyads who preferred the new
disposable pen (n = 79) and rated the new disposable
pen “very easy” to use ranged from 62.0% to 94.9% com-
pared to 30.4% to 87.0% for those who preferred the re-
usable pen (n = 46) and rated the reusable pen “very
easy” to use. For Items 2b and 2d (preparing the injec-
tion pen and removing the air bubbles) it is interesting
to note that of dyads who preferred the reusable pen,
only 30% rated these attributes as “very easy”. This may
suggest that for some attributes, habituation may influ-
ence preference (i.e., it may not be easy, but the person
is used to it and prefers to keep using the pen).
In this analysis, an ICC of less than 0.30 was consid-
ered the cut-off for showing a relationship to preference
(i.e., correlations <0.30 suggest a relationship to prefer-
ence) by demonstrating inconsistency in responses
across both injection pens (e.g., having higher ratings for
the “remembering the dose” item when assessing the re-
usable pen compared to the new disposable pen for
dyads who preferred the reusable pen). For those that
preferred the reusable pen, all but two attributes (ease or
difficulty of using the injection pen overall and attaching
and removing the needle) were related to preference
based on the ICCs (Tables 10). Six attributes demon-
strated significant differences in scores between the twoinjection pens (mixing the medicine, remembering the
dose prescribed by the doctor, changing the dose when
the doctor changes the prescription, using the needle
guard, knowing when the injection pen has finished
injecting the medicine, and handling the injection pen
while preparing and injecting the medicine). For those
that preferred the new disposable pen, all attributes were
related to preference based on the ICCs (Table 11). All
but 4 attributes (setting the dose, changing the dose
when the doctor changes the prescription, handling the
injection pen while preparing and injecting the medicine,
and storing the injection pen in the refrigerator) demon-
strated significant differences in scores between the two
injection pens.
Summary
The IPAQ was specifically designed to measure ease of
use and preference of Genotropin injection pens in
dyads being treated with hGH. Previous qualitative work
to develop the IPAQ in dyads using the reusable pen
suggests that the IPAQ has 4 subscales measuring ease
of use: preparing the pen, setting the dose, injecting the
medicine and maintaining the pen. In addition, these
subscales can be combined into a total score.
Individual responses for the ease of use items (Section I)
and subscale scores demonstrated ceiling effects. These
results may reflect the ease of these injection pens and the
positive attitudes towards using these pens or prior experi-
ence taking hGH among the study sample. These findings
are not unexpected and are consistent with other studies
evaluating ease of use with injection devices where subject
ratings are skewed towards the most favorable responses
[3,17-21].
The CFA provide evidence supporting a second order
factor solution for four subscales (preparing the pen, set-
ting the dose, injecting the medicine and maintaining
the pen) and a total score (total IPAQ score). These fac-
tor analysis results support the conceptual framework
developed from previous qualitative research in patient
dyads using the reusable pen [22].
The IPAQ did not demonstrate internal consistency
reliability above the 0.70 threshold for group level com-
parisons for all subscales and this may have been due to
the significant ceiling effects observed in the items. The
findings indicated that the subscale and total IPAQ
scores are internally consistent for only 2 and 1 (of 4
subscales) for the current reusable and new disposable
pens, respectively (Cronbach’s alpha range 0.53 to 0.82).
Cronbach’s alphas for the total IPAQ score for both pens
are 0.85, exceeding acceptable levels of reliability for
group comparisons. This study provides evidence sup-
porting construct validity of the IPAQ in subjects being
treated with hGH, where subscale and total IPAQ scores
were moderately or strongly, significantly related to








1. Ease or difficulty of using the injection pen overall 46 4.54 (0.84) 4.59 (0.88) 0.04 (1.01) 0.7717 0.31
2a. Attaching and removing the needle 46 3.80 (1.09) 4.07 (1.04) 0.26 (1.25) 0.1655 0.30
2b. Preparing the injection pen by changing the cartridge or getting a new injection pen 46 4.26 (1.00) 4.50 (0.69) 0.24 (1.02) 0.1171 0.29
2c. Mixing the medicine 46 3.74 (1.10) 4.33 (0.90) 0.59 (1.24) 0.0024 0.21
2d. Removing the air bubbles 46 4.72 (0.54) 4.65 (0.67) −0.07 (0.80) 0.5831 0.15
2e. Remembering the dose that was prescribed by the doctor 46 4.80 (0.58) 4.17 (1.16) −0.63 (1.32) 0.0023 −0.03
2f. Setting the dose 9 4.89 (0.33) 4.67 (0.71) −0.22 (0.83) 0.4468 −0.14
2g. Changing the dose when the doctor changes the prescription 35 4.77 (0.55) 4.17 (1.15) −0.60 (1.17) 0.0045 0.13
2h. Using the needle guard 46 4.30 (0.96) 3.28 (1.29) −1.02 (1.63) 0.0001 −0.01
2i. Injecting the medicine 46 3.65 (1.29) 3.59 (1.36) −0.07 (1.72) 0.7980 0.16
2j. Knowing when the injection pen has finished injecting the medicine 46 4.35 (0.90) 3.61 (1.27) −0.74 (1.37) 0.0007 0.19
2k. Handling the injection pen while preparing and injecting the medicine 46 4.70 (0.76) 4.00 (1.41) −0.70 (1.55) 0.0038 0.06
2l. Storing the injection pen in the refrigerator 46 4.61 (0.80) 4.41 (0.88) −0.20 (1.09) 0.2288 0.17
1Difference = Visit 3 - Visit 1.
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pen. In addition, evidence is provided for the predictive
validity of the total IPAQ score predicting preference for
the new disposable pen.
The IPAQ was developed for application in trials com-
paring ease of use and preference between these specific
injection pens with regard to injection pen attributes.
Findings from this research suggest the suitability for
use of a total IPAQ score for ease of use and the single
ease of use item. CFA supports the use of subscale
scores to assess ease of use. The psychometric properties
of these subscales, mainly the less than desirable internal
consistency reliability of some of the subscales and the
predictive validity findings, do not support the use ofTable 11 ICCs of IPAQ items for dyads who preferred the New
Item
1. Ease or difficulty of using the injection pen overall
2a. Attaching and removing the needle
2b. Preparing the injection pen by changing the cartridge or getting a new i
2c. Mixing the medicine
2d. Removing the air bubbles
2e. Remembering the dose that was prescribed by the doctor
2f. Setting the dose
2g. Changing the dose when the doctor changes the prescription
2h. Using the needle guard
2i. Injecting the medicine
2j. Knowing when the injection pen has finished injecting the medicine
2k. Handling the injection pen while preparing and injecting the medicine
2l. Storing the injection pen in the refrigerator
1Difference = Visit 3 - Visit 1.subscale scores alone. The subscale scores, however, do
provide additional information regarding the perform-
ance of the pens as seen by the subject dyads. As such, it
is recommended that the total IPAQ score is used as the
primary ease of use endpoint because of its evidence on
reliability and validity, and because it is a construct that
is important to patients and their caregivers [22]. The
subscale scores can be used to examine reasons for any
observed differences in total IPAQ scores, and to pro-
vide more insight into injection pen attribute prefer-
ences. The IPAQ ease of use item may be useful in trials
to get information about ease of use with different injec-
tion devices - though such application would require








79 4.59 (0.81) 4.92 (0.27) 0.33 (0.78) 0.0003 0.14
79 3.77 (1.01) 4.78 (0.44) 1.01 (1.06) <0.0001 0.05
njection pen 79 4.15 (0.93) 4.76 (0.51) 0.61 (1.01) <0.0001 0.08
79 3.73 (1.16) 4.75 (0.54) 1.01 (1.14) <0.0001 0.13
79 4.76 (0.60) 4.95 (0.22) 0.19 (0.66) 0.0127 -.06
79 4.56 (0.92) 4.84 (0.46) 0.28 (0.96) 0.0118 0.12
13 4.54 (0.97) 4.85 (0.55) 0.31 (1.18) 0.3665 -.13
61 4.56 (0.70) 4.75 (0.57) 0.20 (0.81) 0.0636 0.17
79 4.23 (1.02) 4.54 (0.81) 0.32 (1.28) 0.0305 0.05
79 3.25 (1.36) 4.37 (0.92) 1.11 (1.46) <0.0001 0.15
79 4.09 (0.94) 4.66 (0.71) 0.57 (1.12) <0.0001 0.08
79 4.70 (0.72) 4.61 (0.87) −0.09 (1.08) 0.4666 0.09
78 4.59 (0.69) 4.60 (0.86) 0.01 (0.96) 0.9064 0.24
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information on patient and caregiver impressions of ease
of use for injection devices; and findings from this study
suggest that the overall impression of ease of use is pre-
dictive of preference for the new disposable pen. The
single-item measure is not recommended as a primary
endpoint for clinical trials, however, since it is less reli-
able than the multi-item total IPAQ score.
In conclusion, the total IPAQ score for ease of use
demonstrated good internal consistency reliability and
good construct validity in measuring ease of use with
the GenotropinW injection pens to administer hGH. Evi-
dence of the psychometric properties of the IPAQ is im-
portant to support claims of potential treatment benefit
for the FDA [11,23,24]. Since this study was conducted
only in the USA and only in experienced GenotropinW
Pen users, further research is needed to confirm these
findings with GenotropinW and new disposable pens in
other countries and in treatment naïve patients. Since
hGH is also used in adults, a study of ease of use in that
population would be of interest with regard to the
IPAQs operating characteristics. Overall, the IPAQ is a
useful measure for evaluating ease of use and preference
for GenotropinW injection pens in clinical trials among
patient dyads receiving hGH.
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